'Quick, Affordable' Test Helps Predict CGRP Response for Migraine

Testing for nonictal cephalic allodynia can help determine with high accuracy which migraine patients will (and which will not) respond to treatment with the anti-CGRP agent galcanezumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/988530?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost